These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32539659)

  • 21. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
    Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
    Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between discoid lupus erythematosus and cigarette smoking.
    Miot HA; Bartoli Miot LD; Haddad GR
    Dermatology; 2005; 211(2):118-22. PubMed ID: 16088157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of smoking with cutaneous manifestations in systemic lupus erythematosus.
    Bourré-Tessier J; Peschken CA; Bernatsky S; Joseph L; Clarke AE; Fortin PR; Hitchon C; Mittoo S; Smith CD; Zummer M; Pope J; Tucker L; Hudson M; Arbillaga H; Esdaile J; Silverman E; Chédeville G; Huber AM; Belisle P; ; Pineau CA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1275-80. PubMed ID: 23401335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.
    Albrecht J; Taylor L; Berlin JA; Dulay S; Ang G; Fakharzadeh S; Kantor J; Kim E; Militello G; McGinnis K; Richardson S; Treat J; Vittorio C; Van Voorhees A; Werth VP
    J Invest Dermatol; 2005 Nov; 125(5):889-94. PubMed ID: 16297185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.
    Hinduja N; Mv P; Padhee S; Maikap D; Padhan P; Kar HK; Misra R; Srinivas CR; Ahmed S
    Rheumatol Int; 2023 Oct; 43(10):1835-1840. PubMed ID: 37310437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.
    Jolly M; Kazmi N; Mikolaitis RA; Sequeira W; Block JA
    J Am Acad Dermatol; 2013 Apr; 68(4):618-623. PubMed ID: 23107310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
    Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
    Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.
    Pakchotanon R; Gladman DD; Su J; Urowitz MB
    J Rheumatol; 2018 Jan; 45(1):90-94. PubMed ID: 29142038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.
    Bonilla-Martinez ZL; Albrecht J; Troxel AB; Taylor L; Okawa J; Dulay S; Werth VP
    Arch Dermatol; 2008 Feb; 144(2):173-80. PubMed ID: 18283174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus.
    Rahman P; Gladman DD; Urowitz MB
    J Rheumatol; 1998 Sep; 25(9):1716-9. PubMed ID: 9733451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of alcohol consumption and smoking on disease damage in systemic lupus erythematosus: data from the Korean Lupus Network (KORNET) registry.
    Kim SK; Lee SS; Choe JY; Park SH; Lee H
    Lupus; 2017 Dec; 26(14):1540-1549. PubMed ID: 28478697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of antimalarial-refractory cutaneous lupus erythematosus.
    Callen JP
    Lupus; 1997; 6(2):203-8. PubMed ID: 9061669
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus.
    Sigges J; Biazar C; Landmann A; Ruland V; Patsinakidis N; Amler S; Bonsmann G; Kuhn A;
    Autoimmun Rev; 2013 May; 12(7):694-702. PubMed ID: 23220353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
    Haugaard JH; Dreyer L; Ottosen MB; Gislason G; Kofoed K; Egeberg A
    J Am Acad Dermatol; 2021 Apr; 84(4):930-937. PubMed ID: 33321159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Kato Y; Sugii S; Inada S
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The different faces of cutaneous lupus erythematosus.
    Renner R; Sticherling M
    G Ital Dermatol Venereol; 2009 Apr; 144(2):135-47. PubMed ID: 19357621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.